Page last updated: 2024-12-11
elsamicin a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
elsamicin A: from actinomycete strain J907-21; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5362259 |
| CHEMBL ID | 2106409 |
| SCHEMBL ID | 3988 |
| MeSH ID | M0142780 |
Synonyms (41)
| Synonym |
|---|
| elsamicin a |
| e-87/025 |
| elsamitrucin |
| bbm-2478a |
| bmy-28090 |
| bu-2478a |
| bms-181171 |
| 97068-30-9 |
| nsc-369327 |
| bbm 2478a |
| brn 5214813 |
| elsamitrucinum [inn-latin] |
| 10-o-elsaminosylelsarosylchartarin |
| elsamitrucine [inn-french] |
| benzo(h)(1)benzopyrano(5,4,3-cde)(1)benzopyran-5,12-dione, 10-((2-o-(2-amino-2,6-dideoxy-3-o-methyl-alpha-d-galactopyranosyl)-6-deoxy-3-c-methyl-beta-d-galactopyranosyl)oxy)-6-hydroxy-1-methyl- |
| antibiotic bbm 2478a |
| 2-amino-2,6-dideoxy-3-o-methyl-d-galactose |
| elsamitrucina [inn-spanish] |
| elsamitrucin [usan:inn] |
| bmy 28090 |
| spi 28090 |
| elsamitrucin (usan/inn) |
| D03977 |
| elsamitrucine |
| nsc 369327 |
| unii-ztv0fob6nu |
| ztv0fob6nu , |
| elsamitrucinum |
| elsamitrucina |
| CHEMBL2106409 |
| DB05129 |
| SCHEMBL3988 |
| benzo(h)(1)benzopyrano(5,4,3-cde)(1)benzopyran-5,12-dione, 10-((2-o-(2-amino-2,6-dideoxy-3-o-methyl-.alpha.-d-galactopyranosyl)-6-deoxy-3-c-methyl-.beta.-d-galactopyranosyl)oxy)-6-hydroxy-1-methyl- |
| elsamitrucin [usan] |
| elsamitrucin [inn] |
| bbm-2478 a |
| MGQRRMONVLMKJL-KWJIQSIXSA-N |
| Q5367460 |
| 10-(((2s,3r,4s,5s,6r)-3-(((2r,3r,4r,5s,6r)-3-amino-5-hydroxy-4-methoxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-4,5-dihydroxy-4,6-dimethyltetrahydro-2h-pyran-2-yl)oxy)-6-hydroxy-1-methylbenzo[h]chromeno[5,4,3-cde]chromene-5,12-dione |
| 3-[(2s,3r,4s,5s,6r)-3-[(2r,3r,4r,5s,6r)-3-amino-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-8-hydroxy-15-methyl-11,18-dioxapentacyclo[10.6.2.02,7.09,19.016,20]icosa-1(19),2(7),3,5,8,12(20),13,15-octaene-10,17-dione |
| DTXSID101028137 |
Research Excerpts
Overview
Elsamicin A is an antitumor antibiotic with fascinating chemical structure. It is a good candidate for pharmaceutical development.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Elsamicin A is an antitumor antibiotic with fascinating chemical structure and a good candidate for pharmaceutical development. " | ( Product analyses in DNA strand scission by antitumor antibiotic elsamicin A. Sugiura, Y; Uesugi, M, 1992) | 1.96 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cardiotoxicity, a side-effect that can occur after treatment with an anticancer drug, has severe clinical implications." | ( In vitro screening of antitumour agents for cardiotoxicity by means of isolated mouse left atria. Bast, A; Haenen, GR; van Acker, FA; van Acker, SA; van der Vijgh, WJ, ) | 0.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (19)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (26)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (11.54) | 18.7374 |
| 1990's | 20 (76.92) | 18.2507 |
| 2000's | 3 (11.54) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.41
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.41) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 6 (20.00%) | 5.53% |
| Reviews | 1 (3.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 23 (76.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [NCT00090090] | Phase 2 | 114 participants | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||